Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy

Proteolysis-targeting chimera (PROTAC) has been developed to be a useful technology for targeted protein degradation. A bifunctional PROTAC molecule consists of a ligand (mostly small-molecule inhibitor) of the protein of interest (POI) and a covalently linked ligand of an E3 ubiquitin ligase (E3)....

Full description

Saved in:

Bibliographic Details
Published in:	Journal of hematology and oncology Vol. 13; no. 1; pp. 50 - 14
Main Authors:	Li, Xin, Song, Yongcheng
Format:	Journal Article
Language:	English
Published:	London BioMed Central 13.05.2020 BioMed Central Ltd Springer Nature B.V BMC
Subjects:	Animals Antineoplastic agents Antineoplastic Agents - chemistry Antineoplastic Agents - pharmacokinetics Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Breast cancer Cancer Cancer Research Cancer therapies Cancer therapy Cancer treatment Cell growth Clinical trials Degradation Drug Discovery Drug dosages Gene expression Health aspects Hematological malignancies Hematology Humans Leukemia Ligands Ligases Lymphoma Medicine Medicine & Public Health Molecular Targeted Therapy Neoplasms - drug therapy Neoplasms - metabolism Nucleic acids Oncology Pharmacodynamics Pharmacokinetics PROTAC Proteasomes Proteins Proteolysis Proteolysis - drug effects Review RNA polymerase Targeted protein degradation Technology application Therapeutic targets Ubiquitin Ubiquitin-protein ligase Ubiquitination Ubiquitination - drug effects PROTAC Targeted protein degradation Cancer therapy Hematological malignancies
ISSN:	1756-8722, 1756-8722
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!